Topical calcineurin inhibitors, including tacrolimus and pimecrolimus, have been shown to alleviate AD symptoms by suppressing the gene transcription of critical AD-related cytokines such as IL-2, IL-4, and IL-5. Here, IL5 is linked to Alzheimer disease.